Last reviewed · How we verify
ZOSTAVAX™ (concomitant)
ZOSTAVAX is a live attenuated vaccine that stimulates an immune response against the varicella-zoster virus.
ZOSTAVAX is a live attenuated vaccine that stimulates an immune response against the varicella-zoster virus. Used for Prevention of herpes zoster (shingles) in adults 50 years of age and older.
At a glance
| Generic name | ZOSTAVAX™ (concomitant) |
|---|---|
| Also known as | V211 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing a weakened form of the varicella-zoster virus to the body, which triggers an immune response and helps to build immunity against future infections. The immune response is then boosted by the presence of the virus, allowing the body to recognize and attack the virus more effectively.
Approved indications
- Prevention of herpes zoster (shingles) in adults 50 years of age and older
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
- Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) (PHASE3)
- ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) (PHASE3)
- A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |